Masupirdine (SUVN‐502): A promising clinical candidate for the management of agitation in Alzheimer’s dementia

Background Masupirdine is a potent and selective 5‐HT6 receptor antagonist and has completed Phase‐2 clinical proof of concept studies in patients with Alzheimer’s type dementia. 5‐HT6 receptors are G‐protein coupled receptors mainly localized in the brain regions primarily involved in cognition and...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Alzheimer's & dementia 2021-12, Vol.17 (S6), p.n/a
Hauptverfasser:	Nirogi, Ramakrishna, Jayarajan, Pradeep, Tadiparthi, Jayaprakash, Shinde, Anil K, Rasheed, Mohammed Abdul, Goyal, Vinod Kumar, Bhyrapuneni, Gopinadh, Benade, Vijay, Palacharla, Veera Raghava Chowdary, Ravula, Jyothsna, Jetta, Satish
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!